^
Association details:
| Biomarker: | MTAP deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | IDE397 (MAT2A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1644 / 1 - Dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer
Published date:
03/15/2023
Excerpt:
In vivo, the combination of IDE397 and MTA-cooperative PRMT5 inhibitors were well tolerated, and induced durable tumor regressions, including complete responses, at dose levels well below the maximally efficacious preclinical dose of each individual agent in MTAPdel lung adenocarcinoma and pancreas cancer models H838 and BXPC3.
Secondary therapy:
PRMT5 inhibitor
